A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

This study — called the ROCSTAR study — is testing a new investigational drug called ROC-101 in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (ILD-PH). Pulmonary hypertension means the blood pressure in the arteries leading to the lungs is dangerously high. **You may be eligible if...** - You are 18 years old or older - You have a confirmed diagnosis of WHO Group 1 (PAH) or WHO Group 3 (pulmonary hypertension with lung disease) based on a right heart catheterization - Your pulmonary hypertension symptoms are classified as moderate (WHO Functional Class II or III) - You have elevated pulmonary vascular resistance and meet specific pressure thresholds on testing **You may NOT be eligible if...** - You have severe pulmonary hypertension symptoms (WHO Functional Class IV) - You have other serious cardiovascular or respiratory conditions that may complicate participation - You do not meet the specific pressure and resistance measurements required Talk to your doctor to see if this trial is right for you.